Ken Griffin Atai Life Sciences N.V. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,575,994 shares of ATAI stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,575,994

Previous 1,179,543 118.39%

Holding current value

$10.3 Million

Previous $2.58 Million 427.56%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.62 - $5.61 $3.66 Million - $7.83 Million	1,396,451 Added 118.39%	2,575,994 $13.6 Million
Q2 2025 Aug 14, 2025	BUY	$1.21 - $2.49 $1.4 Million - $2.87 Million	1,154,511 Added 4612.14%	1,179,543 $2.58 Million
Q1 2025 May 15, 2025	SELL	$1.33 - $2.55 $521,014 - $998,936	-391,740 Reduced 93.99%	25,032 $34,000
Q4 2024 Feb 14, 2025	BUY	$1.06 - $1.78 $441,778 - $741,854	416,772 New	416,772 $554,000
Q2 2024 Aug 14, 2024	SELL	$1.27 - $2.6 $387,021 - $792,326	-304,741 Reduced 99.0%	3,085 $4,000

Q1 2024 May 15, 2024	SELL	$1.5 - $2.19 $177,421 - $259,035	-118,281 Reduced 27.76%	307,826 $606,000
Q4 2023 Feb 14, 2024	BUY	$1.04 - $1.55 $443,151 - $660,465	426,107 New	426,107 $600,000
Q2 2023 Aug 14, 2023	BUY	$1.44 - $2.19 $71,677 - $109,009	49,776 Added 15902.88%	50,089 $86,000
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $14,730 - $33,993	-12,590 Reduced 97.57%	313 $0
Q4 2022 Feb 14, 2023	SELL	$2.38 - $3.55 $2.42 Million - $3.61 Million	-1,017,013 Reduced 98.75%	12,903 $34,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $2.37 Million - $3.67 Million	754,242 Added 273.6%	1,029,916 $3.41 Million

Others Institutions Holding ATAI

# of Institutions

149

Shares Held

45.8M

Call Options Held

1.88M

Put Options Held

543K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $664M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account